Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Minimal deviation melanoma.

Podnos YD, Jimenez JC, Zainabadi K, Jakowatz JG, Barr RJ.

Cancer Treat Rev. 2002 Oct;28(5):219-21. Review.

PMID:
12435369
2.

Minimal deviation melanoma. Borderline and intermediate melanocytic neoplasia.

Reed RJ.

Clin Lab Med. 2000 Dec;20(4):745-58. Review.

PMID:
11221513
3.

Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis.

George E, McClain SE, Slingluff CL, Polissar NL, Patterson JW.

J Cutan Pathol. 2009 Apr;36(4):425-32. doi: 10.1111/j.1600-0560.2008.01058.x.

PMID:
19278427
4.

Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.

Gannon CJ, Rousseau DL Jr, Ross MI, Johnson MM, Lee JE, Mansfield PF, Cormier JN, Prieto VG, Gershenwald JE.

Cancer. 2006 Dec 1;107(11):2647-52.

5.

Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis.

Livestro DP, Kaine EM, Michaelson JS, Mihm MC, Haluska FG, Muzikansky A, Sober AJ, Tanabe KK.

Cancer. 2007 Aug 1;110(3):614-24.

6.

Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents.

Roaten JB, Partrick DA, Pearlman N, Gonzalez RJ, Gonzalez R, McCarter MD.

J Pediatr Surg. 2005 Jan;40(1):232-5.

PMID:
15868590
7.

Minimal deviation and/or naevoid melanoma: is recognition worthwhile? A clinicopathological study of nine cases.

Stas M, van den Oord JJ, Garmyn M, Degreef H, De Wever I, De Wolf-Peeters C.

Melanoma Res. 2000 Aug;10(4):371-80.

PMID:
10985672
8.

Tumour regression does not increase the risk of sentinel node involvement in thin melanomas.

Cecchi R, Pavesi M, Buralli L, Innocenti S, De Gaudio C.

Chir Ital. 2008 Mar-Apr;60(2):257-60.

PMID:
18689175
9.

Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.

Kesmodel SB, Karakousis GC, Botbyl JD, Canter RJ, Lewis RT, Wahl PM, Terhune KP, Alavi A, Elder DE, Ming ME, Guerry D, Gimotty PA, Fraker DL, Czerniecki BJ, Spitz FR.

Ann Surg Oncol. 2005 Jun;12(6):449-58. Epub 2005 Apr 19.

PMID:
15864482
10.

[Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].

Keijzer R, Bril H, van der Loo EM, de Graaf PW.

Ned Tijdschr Geneeskd. 2004 May 1;148(18):884-8. Dutch.

PMID:
15152391
11.

Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.

Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS.

J Clin Oncol. 2007 Mar 1;25(7):869-75.

PMID:
17327608
12.

Disease progression in patients with thin cutaneous melanomas (tumour thickness < or = 0.75 mm): clinical and epidemiological data from the Tumour Center Munich 1977-98.

Schmid-Wendtner MH, Baumert J, Eberle J, Plewig G, Volkenandt M, Sander CA.

Br J Dermatol. 2003 Oct;149(4):788-93.

PMID:
14616371
13.

The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.

Paek SC, Griffith KA, Johnson TM, Sondak VK, Wong SL, Chang AE, Cimmino VM, Lowe L, Bradford CR, Rees RS, Sabel MS.

Cancer. 2007 Jan 1;109(1):100-8.

14.

Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.

Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM.

Arch Dermatol. 2005 Aug;141(8):1016-22.

PMID:
16103331
15.

Sentinel lymph node biopsy in patients with thin melanoma.

Lowe JB, Hurst E, Moley JF, Cornelius LA.

Arch Dermatol. 2003 May;139(5):617-21.

PMID:
12756098
16.

Significance of multiple lymphatic basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy.

McHugh JB, Su L, Griffith KA, Schwartz JL, Wong SL, Cimmino V, Chang AE, Johnson TM, Sabel MS.

Ann Surg Oncol. 2006 Sep;13(9):1216-23. Epub 2006 Sep 3.

PMID:
16952026
17.

Significance of dual-basin drainage in patients with truncal melanoma undergoing sentinel lymph node biopsy.

Jacobs IA, Chang CK, Salti GI.

J Am Acad Dermatol. 2003 Oct;49(4):615-9.

PMID:
14512905
18.

Sentinel lymph node biopsy for melanoma: indications and rationale.

Phan GQ, Messina JL, Sondak VK, Zager JS.

Cancer Control. 2009 Jul;16(3):234-9. Review.

19.

Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.

Chorny JA, Barr RJ, Kyshtoobayeva A, Jakowatz J, Reed RJ.

Mod Pathol. 2003 Jun;16(6):525-9.

20.

Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review.

Gipponi M, Di Somma C, Peressini A, Solari N, Gliori S, Nicolo G, Schenone F, Queirolo P, Sertoli MR, Cafiero F.

J Surg Oncol. 2004 Mar;85(3):133-40. Review.

PMID:
14991885

Supplemental Content

Support Center